NORTHWEST BIOTHERAPEUTICS INC — Earnings
Most recent reported period: FY2025 (Q4) (filed for period ending 2025-12-31) · sourced from SEC EDGAR
Next earnings (estimated): Wed, April 1, 2026 — 31 days overdue (likely already filed but EDGAR cache cold). Anchored to latest quarter-end + 91 days. Analyst-confirmed dates land in a follow-up wave.
YoY = vs same quarter prior year (seasonality-adjusted)
Recent earnings · last 8 quarters
| Quarter end | Revenue | YoY | Net Income | YoY | Op. Margin |
|---|---|---|---|---|---|
| 2025-12-31 | $672K | ↑+190.9% | — | — | — |
| 2025-09-30 | $200K | ↓-44.0% | $-27M | ↓-38.5% | -7160.0% |
| 2025-06-30 | $131K | ↓-74.3% | $-15M | ↑+13.9% | -11281.7% |
| 2025-03-31 | $375K | ↑+32.0% | $-19M | ↓-5.6% | -4616.3% |
| 2024-12-31 | $231K | ↓-48.1% | — | — | — |
| 2024-09-30 | $357K | ↓-12.1% | $-19M | ↑+17.6% | -4145.9% |
| 2024-06-30 | $510K | ↑+153.7% | $-18M | ↓-23.7% | -3424.3% |
| 2024-03-31 | $284K | ↓-67.7% | $-18M | ↓-71.9% | -5543.7% |
Analyst consensus estimates (EPS / Revenue) and implied move from options will land in a follow-up wave. For now, YoY-vs-prior-year-quarter is the surprise proxy.
Last earnings · FY2025 (Q4)
Revenue
$672K
↑+190.9% +$441K YoY
Earnings surprise · last 8 quarters
YoY % change · proxy for analyst surprise until estimates landEPS history · last 10 fiscal years
diluted, GAAP, annualNote: EPS reflects WEIGHTED-AVERAGE diluted shares for each fiscal year. Pre-stock- split values can blow up the early bars if SEC's XBRL data isn't split-adjusted — flagged as a known limitation; cumulative split-adjustment is a follow-up.
Go deeper
NWBO Sankey — flow of dollars
See how revenue waterfalls through every line item to net income for the latest reported quarter, with prior-period comparison.
Open SankeyNWBO Key Metrics — EPS, ROE, ROIC
10 CFA-grade fundamental ratios — EPS, BVPS, ROE, ROA, ROIC, Debt/Equity, Current Ratio. Compare across years.
Open Key Metrics